RxSight, Inc.

Annual Trend FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Total Revenue $14.7m
$22.6m +53.92%
$49.0m +116.90%
$89.1m +81.77%
$139.9m +57.09%
$134.5m -3.89%
$127.6m -5.13%
Cost of Revenue $13.0m
$18.1m +39.34%
$27.7m +53.11%
$35.3m +27.59%
$41.0m +16.06%
$31.5m -23.21%
$28.7m -8.78%
Net Interest Income ($3.4m)
$3.3m +195.25%
$9.5m +189.44%
$9.3m -1.48%
$8.3m -11.16%
Gross Profit $1.7m
$4.5m +164.93%
$21.3m +372.17%
$53.8m +152.09%
$98.9m +84.03%
$103.0m +4.11%
$98.9m -4.01%
Research And Development $21.9m $24.5m $26.0m $29.1m $34.4m $38.5m $36.7m
Operating Expenses $37.1m $57.3m $84.6m $103.8m $135.8m $151.2m $154.0m
Operating Income (Loss) ($35.4m)
($52.8m) -49.07%
($63.3m) -19.95%
($50.1m) +20.90%
($36.9m) +26.41%
($48.2m) -30.75%
($55.1m) -14.36%
Interest Expense $510k $3.7m $4.9m $3.3m $21k $19k $14k
Interest Income $54k $1.5m $6.6m $9.5m $9.3m $8.3m
Net Non Operating Interest Income Expense ($3.4m) $3.3m $9.5m $9.3m $8.3m
Interest and Other Income $54k $1.5m $6.6m $9.5m $9.3m
Other Income Expense $7.7m ($1.8m)
Income (Loss) from Continuing Operations before Income Taxes, Domestic $27.6m ($48.7m) ($66.8m) ($48.6m) ($27.4m) ($38.9m) ($46.8m)
Pre-Tax Income $27.6m ($48.7m) ($66.7m) ($48.6m) ($27.4m) ($38.9m) ($46.8m)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $27.6m ($48.7m) ($66.7m) ($48.6m) ($27.4m) ($38.9m) ($46.8m)
Current Income Tax Expense (Benefit) $57k $8k $9k $20k $50k $66k $110k
Net Income From Continuing And Discontinued Operation $27.6m ($48.7m) ($66.8m) ($48.6m) ($27.5m) ($38.9m) ($46.9m)
Earnings Per Share, Basic $0.91 ($3.57) ($2.41) ($1.41) ($0.71) ($0.95) ($1.14)
Earnings Per Share, Diluted $0.15 ($3.57) ($2.41) ($1.41) ($0.71) ($0.95) ($1.14)
Weighted Average Number of Shares Outstanding, Basic 3.7m 13.6m 27.7m 34.5m 38.9m 40.9m 41.2m
Basic Average Shares 3.7m 13.6m $27.7m $34.5m $38.9m $40.9m $41.2m
Diluted Average Shares 3.7m 13.6m $27.7m $34.5m $38.9m $40.9m $41.2m
Weighted Average Number of Shares Outstanding, Diluted 5.5m 13.6m 27.7m 34.5m 38.9m 40.9m 41.2m
Additional Financial Items
Diluted EPS $0.91 ($3.57) ($2.41) ($1.41) ($0.71) ($0.95) ($1.14)
Diluted NI Availto Com Stockholders $27.6m ($48.7m) ($66.8m) ($48.6m) ($27.5m) ($38.9m) ($46.9m)
Normalized EBITDA ($57.8m) ($39.4m) ($23.8m) ($35.6m) ($43.3m)
Normalized Income ($66.8m) ($46.8m) ($27.5m) ($38.9m) ($46.9m)
Reconciled Depreciation $4.0m $4.1m $3.6m $3.3m $3.5m
Selling General And Administration $15.2m $32.8m $58.7m $74.8m $101.4m $112.7m
Special Income Charges $0 ($1.8m) $0 $0 $0
Tax Effect Of Unusual Items $0 $0 $0 $0 $0
Tax Provision $57k $8k $9k $20k $50k $66k $110k
Tax Rate For Calcs $0 $0 $0 $0 $0
Cost, Depreciation and Amortization $3.9m $4.0m $3.9m $4.1m $3.6m $3.3m
Total Unusual Items $0 ($1.8m) $0 $0 $0
Total Expenses $112.3m $139.2m $176.8m $182.7m $182.7m